<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01350999</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-085/OCT-001</org_study_id>
    <secondary_id>JapicCTI-090936</secondary_id>
    <secondary_id>U1111-1120-7892</secondary_id>
    <secondary_id>JapicCTI-R140451</secondary_id>
    <nct_id>NCT01350999</nct_id>
  </id_info>
  <brief_title>Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia</brief_title>
  <official_title>A Phase 3 Long-term Study of TAK-085 in Subjects With Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of TAK-085, once daily (QD)
      or twice daily (BID), compared to ethyl eicosapentaenoate (EPA-E), three times daily (TID) in
      participants with hypertriglyceridemia undergoing lifestyle modification.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TAK-085 is an oral capsule medicine licensed to Takeda Pharmaceutical Company Ltd. TAK-085
      contains omega-3 fatty acid ethyl (mainly, ethyl eicosapentaenoate (EPA-E) and ethyl
      docosahexaenoic acid (DHA-E)).

      This is a phase 3, open-label, randomized study to evaluate the efficacy and safety of
      TAK-085. In addition, EPA-E is also administered for 52 weeks for reference to evaluate the
      safety of TAK-085 in participants with hypertriglyceridemia who are undergoing lifestyle
      modification.

      The study period is a total of 56 weeks, comprised of a 4- week screening period and 52 weeks
      of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs Associated With Abnormal Changes in Vital Signs</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs Associated With Abnormal Changes in Body Weight</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Findings in Electrocardiogram After Study Drug Administration</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Participants whose results of electrocardiograms were judged as abnormal and clinically significant by investigator after study drug administration were counted in this measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Chemistry, Hematology or Urinalysis</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglyceride Level</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Low-Density Lipoprotein - Cholesterol (LDL-C)</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High-Density Lipoprotein - Cholesterol (HDL-C)</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-High-Density Lipoprotein - Cholesterol</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
    <description>Non-high-density lipoprotein cholesterol was calculated by subtracting high-density lipoprotein cholesterol from total cholesterol.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">503</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>TAK-085 2 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-085 2 g, orally, once daily for up to 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-085 4 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-085 2 g, orally, twice daily for up to 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPA-E 1.8 g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega-3-acid ethyl esters 90 (TAK-085)</intervention_name>
    <description>Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.</description>
    <arm_group_label>TAK-085 2 g</arm_group_label>
    <arm_group_label>TAK-085 4 g</arm_group_label>
    <other_name>LOVAZA</other_name>
    <other_name>Omacor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eicosapentaenoic acid-ethyl (EPA)</intervention_name>
    <description>EPA-E capsules</description>
    <arm_group_label>EPA-E 1.8 g</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Visit 1 (Week -4)

          1. Undergoing lifestyle modification.

          2. Triglyceride (TG) level (fasting state) 150 mg/dL or higher and less than 750 mg/dL at
             Visit 1 (Week -4).

          3. Both genders, aged from 20 to less than 75 years at the time of signing informed
             consent.

          4. Outpatient.

          5. Capable of understanding and complying with protocol requirements.

          6. Signed a written, informed consent form prior to the initiation of any study
             procedures.

          7. A female with childbearing potential (premenopausal and non-sterilized) must have
             agreed to use routinely adequate contraception from signing of informed consent
             throughout the duration of the study.

             Visit 2 (Week -2)

          8. Fasting TG level 150 mg/dL or higher and less than 750 mg/dL at Visit 2 (Week -2).

          9. Difference in fasting low density lipoprotein-cholesterol (LDL-C) level between Visit
             1 (Week -4) and Visit 2 (Week -2) within 25% of the higher value

        Exclusion Criteria:

        Visit 1 (Week -4)

          1. Any coronary artery diseases (CAD, e.g., confirmed myocardial infarction and angina
             pectoris) within 6 months prior to Visit 1 (Week -4) or a history of
             revascularization.

          2. Received aortic aneurysmectomy or had had aortic aneurysm within 6 months prior to
             Visit 1 (Week -4).

          3. History or complication of a clinically significant hemorrhagic disease (e.g.,
             hemophilia, capillary fragility illness, digestive tract ulcer, urinary tract
             haemorrhage, hemoptysis, vitreous haemorrhage) within 6 months prior to Visit 1 (Week
             -4).

          4. Diagnosed with pancreatitis.

          5. Diagnosed with lipoprotein lipase (LPL) deficiency, apolipoprotein C-II deficiency or
             type III familial hyperlipidemia.

          6. Cushing's syndrome, uremia, systemic lupus erythematosus (SLE) or serum
             dysproteinemia.

          7. Type 1 diabetes mellitus or with uncontrolled type 2 diabetes mellitus defined by
             glycosylated hemoglobin (HbA1C) level of 8.0% or higher at Visit 1 (Week -4).

          8. Stage III hypertension defined by systolic blood pressure of 180 mmHg or higher or
             diastolic blood pressure of 110 mmHg or higher regardless of the use of
             antihypertensive medication.

          9. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level at Visit 1
             (Week -4) was not less than twice the upper limit of the normal reference range.

         10. If female, was pregnant or lactating.

         11. Habitual drinking defined by an average daily alcohol intake of 100 mL or more , drug
             abuse or drug dependency, or a history of any of these conditions.

         12. Started to take any antihyperlipidemic drugs within 4 weeks prior to Visit 1 (Week
             -4).

         13. Received any investigational products (including those for post-marketing clinical
             study) within 12 weeks prior to Visit 1 (Week -4).

         14. Received TAK-085 in a clinical study.

         15. Judged as being ineligible for study participation by the investigator or
             subinvestigator for any other reasons.

             Visit 2 (Week -2)

         16. ALT or AST level at Visit 2 (Week -2) was twice the upper limit of the normal
             reference range or higher.

         17. Needed a change in the dose of antihyperlipidemic drugs or antidiabetic drugs,
             addition of a new drug or a change in the type of the drugs during the screening
             period.

         18. Judged as being ineligible for study participation by the investigator or
             subinvestigator for any other reasons.

             Visit 3 (Week 0)

         19. Needed a change in the dose of antihyperlipidemic drugs or antidiabetic drugs,
             addition of a new drug or a change in the type of the drugs during the screening
             period.

         20. Judged as being ineligible for study participation by the investigator or
             subinvestigator for any other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Associate Professor, Clinical Cell Biology and Medicine</last_name>
    <role>Study Director</role>
    <affiliation>Graduate School of Medicine, Chiba University</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>May 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2011</study_first_posted>
  <results_first_submitted>June 1, 2016</results_first_submitted>
  <results_first_submitted_qc>July 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 20, 2016</results_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 50 investigative sites in Japan from 11 November 2009 to 11 January 2011.</recruitment_details>
      <pre_assignment_details>Participants with hypertriglyceridemia were randomized to receive omega-3-acid ethyl esters 90 (TAK-085) 2 g once daily or TAK-085 2 g twice daily or EPA-E 0.6 g three-times daily.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TAK-085 2 g</title>
          <description>TAK-085 2 g capsule, orally, once daily for up to 52 weeks.</description>
        </group>
        <group group_id="P2">
          <title>TAK-085 4 g</title>
          <description>TAK-085 2 g capsules, orally, twice daily for up to 52 weeks.</description>
        </group>
        <group group_id="P3">
          <title>EPA-E 1.8 g</title>
          <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="171"/>
                <participants group_id="P3" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="171"/>
                <participants group_id="P3" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="157"/>
                <participants group_id="P3" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Difficulty Making it to Study Visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TAK-085 2 g</title>
          <description>TAK-085 2 g capsule, orally, once daily for up to 52 weeks.</description>
        </group>
        <group group_id="B2">
          <title>TAK-085 4 g</title>
          <description>TAK-085 2 g capsules, orally, twice daily for up to 52 weeks.</description>
        </group>
        <group group_id="B3">
          <title>EPA-E 1.8 g</title>
          <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="165"/>
            <count group_id="B2" value="171"/>
            <count group_id="B3" value="167"/>
            <count group_id="B4" value="503"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.0" spread="10.95"/>
                    <measurement group_id="B2" value="55.9" spread="10.12"/>
                    <measurement group_id="B3" value="55.8" spread="9.27"/>
                    <measurement group_id="B4" value="55.9" spread="10.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≥20 - &lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="136"/>
                    <measurement group_id="B4" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 - ≤74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="119"/>
                    <measurement group_id="B4" value="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="167"/>
                    <measurement group_id="B4" value="503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopause Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Applicable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="119"/>
                    <measurement group_id="B4" value="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height, Categorical</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;160 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥160 - &lt;170 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥170 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164.2" spread="9.40"/>
                    <measurement group_id="B2" value="164.0" spread="8.69"/>
                    <measurement group_id="B3" value="164.4" spread="9.65"/>
                    <measurement group_id="B4" value="164.2" spread="9.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight, Categorical</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;60 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥60.0 - &lt;70.0 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥70.0 - &lt;80.0 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥80.0 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.02" spread="12.291"/>
                    <measurement group_id="B2" value="70.46" spread="12.097"/>
                    <measurement group_id="B3" value="71.61" spread="13.311"/>
                    <measurement group_id="B4" value="70.70" spread="12.568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index, Categorical</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;25.0 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥25.0 - &lt;30.0 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥30.0 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.90" spread="3.673"/>
                    <measurement group_id="B2" value="26.11" spread="3.526"/>
                    <measurement group_id="B3" value="26.33" spread="3.301"/>
                    <measurement group_id="B4" value="26.12" spread="3.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never Smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference, Categorical</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male &lt;85.0 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male ≥85.0 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female &lt;90.0 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female ≥90.0 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.39" spread="8.607"/>
                    <measurement group_id="B2" value="90.75" spread="9.169"/>
                    <measurement group_id="B3" value="91.16" spread="9.284"/>
                    <measurement group_id="B4" value="90.77" spread="9.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary Artery Disease (CAD) Category</title>
          <description>CAD Patient Categories define the degree of risk of CAD according to Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases. Categories are classified by the degree of risks in the patient [e.g, smoking, hypertension, excluding level of low density lipoprotein cholesterol (LDL-C)]. Category I=Low risk (best), Category II=Middle risk, Category III=High Risk and History of CAD.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Category I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of CAD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Mellitus (Including Impaired Glucose Tolerance)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low High Density Lipoprotein - Cholesterol (HDL-C)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Administration of 3-hydroxy 3-methylglutaryl coenzyme A (HMGCoA) Reductase Inhibitor</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides, Categorical</title>
          <description>The number of participants with available triglyceride data are 164, 169 and 167 in each treatment arm, respectively.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;150 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥150 - &lt;300 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥300 - &lt;500 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥500 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <description>The number of participants with available triglyceride data are 164, 169 and 167 in each treatment arm, respectively.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="254.7" spread="97.80"/>
                    <measurement group_id="B2" value="270.0" spread="101.19"/>
                    <measurement group_id="B3" value="264.2" spread="111.62"/>
                    <measurement group_id="B4" value="263.0" spread="103.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low Density Lipoprotein - Cholesterol (LDL-C), Categorical</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;140 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥140 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low Density Lipoprotein - Cholesterol (LDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133.2" spread="29.85"/>
                    <measurement group_id="B2" value="129.0" spread="30.26"/>
                    <measurement group_id="B3" value="129.3" spread="33.00"/>
                    <measurement group_id="B4" value="130.5" spread="31.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs)</title>
        <time_frame>52 Weeks</time_frame>
        <population>Safety Analysis Set included all participants who received at least one dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g capsule, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g capsules, orally, twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs)</title>
          <population>Safety Analysis Set included all participants who received at least one dose of the investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs Associated With Abnormal Changes in Vital Signs</title>
        <time_frame>52 Weeks</time_frame>
        <population>Safety Analysis Set included all participants who received at least one dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g capsule, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g capsules, orally, twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Associated With Abnormal Changes in Vital Signs</title>
          <population>Safety Analysis Set included all participants who received at least one dose of the investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="12.58"/>
                    <measurement group_id="O2" value="0" spread="12.64"/>
                    <measurement group_id="O3" value="0" spread="12.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs Associated With Abnormal Changes in Body Weight</title>
        <time_frame>52 Weeks</time_frame>
        <population>Safety Analysis Set included all participants who received at least one dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g capsule, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g capsules, orally, twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Associated With Abnormal Changes in Body Weight</title>
          <population>Safety Analysis Set included all participants who received at least one dose of the investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.907"/>
                    <measurement group_id="O2" value="0" spread="0.870"/>
                    <measurement group_id="O3" value="0" spread="0.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Findings in Electrocardiogram After Study Drug Administration</title>
        <description>Participants whose results of electrocardiograms were judged as abnormal and clinically significant by investigator after study drug administration were counted in this measure.</description>
        <time_frame>52 Weeks</time_frame>
        <population>Safety Analysis Set included all participants who received at least one dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g capsule, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g capsules, orally, twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Findings in Electrocardiogram After Study Drug Administration</title>
          <description>Participants whose results of electrocardiograms were judged as abnormal and clinically significant by investigator after study drug administration were counted in this measure.</description>
          <population>Safety Analysis Set included all participants who received at least one dose of the investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Chemistry, Hematology or Urinalysis</title>
        <time_frame>52 Weeks</time_frame>
        <population>Safety Analysis Set included all participants who received at least one dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g capsule, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g capsules, orally, twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Chemistry, Hematology or Urinalysis</title>
          <population>Safety Analysis Set included all participants who received at least one dose of the investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglyceride Level</title>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>Full analysis set (all participants who were randomized and received at least one dose of the investigational product) with available data at each time point (indicated by &quot;n&quot;).</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g capsule, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g capsules, orally, twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglyceride Level</title>
          <population>Full analysis set (all participants who were randomized and received at least one dose of the investigational product) with available data at each time point (indicated by &quot;n&quot;).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=163, 168, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.875" spread="28.1914"/>
                    <measurement group_id="O2" value="-24.550" spread="26.7987"/>
                    <measurement group_id="O3" value="-5.743" spread="35.8469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=162, 166, 163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.474" spread="36.1225"/>
                    <measurement group_id="O2" value="-26.555" spread="24.1354"/>
                    <measurement group_id="O3" value="-5.796" spread="36.2369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=162, 166, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.628" spread="28.6330"/>
                    <measurement group_id="O2" value="-21.689" spread="27.9188"/>
                    <measurement group_id="O3" value="-9.204" spread="34.5555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=160, 165, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.363" spread="35.5523"/>
                    <measurement group_id="O2" value="-20.735" spread="35.0625"/>
                    <measurement group_id="O3" value="-9.522" spread="36.2768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=161, 164, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.965" spread="29.2649"/>
                    <measurement group_id="O2" value="-21.483" spread="28.1817"/>
                    <measurement group_id="O3" value="-7.400" spread="37.9737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=158, 162, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.393" spread="34.8938"/>
                    <measurement group_id="O2" value="-23.863" spread="31.2129"/>
                    <measurement group_id="O3" value="-8.269" spread="38.8420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=159, 159, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.644" spread="33.3250"/>
                    <measurement group_id="O2" value="-25.119" spread="31.4602"/>
                    <measurement group_id="O3" value="-9.422" spread="34.4423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=159, 160, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.464" spread="36.7968"/>
                    <measurement group_id="O2" value="-27.219" spread="27.8708"/>
                    <measurement group_id="O3" value="-9.867" spread="36.9807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=156, 158, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.190" spread="33.2777"/>
                    <measurement group_id="O2" value="-26.535" spread="27.0283"/>
                    <measurement group_id="O3" value="-9.616" spread="42.1895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=159, 158, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.934" spread="35.8353"/>
                    <measurement group_id="O2" value="-25.062" spread="30.7020"/>
                    <measurement group_id="O3" value="-15.345" spread="33.6494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (n=158, 156, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.156" spread="31.8849"/>
                    <measurement group_id="O2" value="-24.402" spread="30.1719"/>
                    <measurement group_id="O3" value="-12.363" spread="38.4921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=156, 155, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.722" spread="33.1045"/>
                    <measurement group_id="O2" value="-26.478" spread="31.4535"/>
                    <measurement group_id="O3" value="-10.185" spread="39.0040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=153, 151, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.219" spread="31.1401"/>
                    <measurement group_id="O2" value="-26.023" spread="28.3644"/>
                    <measurement group_id="O3" value="-13.872" spread="40.9936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Low-Density Lipoprotein - Cholesterol (LDL-C)</title>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>Full analysis set with available data at each time point (indicated by &quot;n&quot;).</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g capsule, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g capsules, orally, twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low-Density Lipoprotein - Cholesterol (LDL-C)</title>
          <population>Full analysis set with available data at each time point (indicated by &quot;n&quot;).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=165, 170, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.219" spread="14.5984"/>
                    <measurement group_id="O2" value="-2.327" spread="17.3965"/>
                    <measurement group_id="O3" value="-3.018" spread="16.3629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=164, 168, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.890" spread="15.7779"/>
                    <measurement group_id="O2" value="-3.209" spread="17.1870"/>
                    <measurement group_id="O3" value="-4.423" spread="16.7481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=163, 168, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.692" spread="15.5025"/>
                    <measurement group_id="O2" value="-4.778" spread="16.2444"/>
                    <measurement group_id="O3" value="-4.542" spread="16.6098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=163, 167, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.689" spread="17.3729"/>
                    <measurement group_id="O2" value="-4.404" spread="18.8456"/>
                    <measurement group_id="O3" value="-4.551" spread="17.6688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=162, 166, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.953" spread="16.1426"/>
                    <measurement group_id="O2" value="-3.088" spread="17.7755"/>
                    <measurement group_id="O3" value="-5.676" spread="17.9077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=159, 164, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.232" spread="14.6688"/>
                    <measurement group_id="O2" value="-0.768" spread="19.6396"/>
                    <measurement group_id="O3" value="-3.623" spread="20.1695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=160, 161, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.660" spread="16.9498"/>
                    <measurement group_id="O2" value="0.421" spread="22.1540"/>
                    <measurement group_id="O3" value="-2.888" spread="17.1272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=160, 163, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.961" spread="17.8059"/>
                    <measurement group_id="O2" value="1.776" spread="21.1586"/>
                    <measurement group_id="O3" value="-1.030" spread="19.2558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=158, 160, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.731" spread="16.7500"/>
                    <measurement group_id="O2" value="2.858" spread="20.9376"/>
                    <measurement group_id="O3" value="0.035" spread="20.9409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=160, 160, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.378" spread="17.4848"/>
                    <measurement group_id="O2" value="2.412" spread="20.8940"/>
                    <measurement group_id="O3" value="-0.037" spread="20.6483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (n=160, 158, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.677" spread="17.2021"/>
                    <measurement group_id="O2" value="2.334" spread="21.0440"/>
                    <measurement group_id="O3" value="0.598" spread="19.6207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=157, 157, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.634" spread="16.2926"/>
                    <measurement group_id="O2" value="2.413" spread="22.0726"/>
                    <measurement group_id="O3" value="-0.306" spread="19.0464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=155, 154, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.374" spread="17.5598"/>
                    <measurement group_id="O2" value="2.993" spread="20.3400"/>
                    <measurement group_id="O3" value="-0.621" spread="16.9016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol</title>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>Full analysis set with available data at each time point (indicated by &quot;n&quot;).</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g capsule, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g capsules, orally, twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol</title>
          <population>Full analysis set with available data at each time point (indicated by &quot;n&quot;).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=165, 170, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.347" spread="9.1943"/>
                    <measurement group_id="O2" value="-6.381" spread="9.8008"/>
                    <measurement group_id="O3" value="-3.386" spread="9.8537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=164, 168, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.510" spread="9.3764"/>
                    <measurement group_id="O2" value="-7.294" spread="9.7792"/>
                    <measurement group_id="O3" value="-3.711" spread="11.0426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=163, 168, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.918" spread="9.1307"/>
                    <measurement group_id="O2" value="-7.316" spread="9.7382"/>
                    <measurement group_id="O3" value="-5.300" spread="10.5662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=163, 167, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.489" spread="10.9503"/>
                    <measurement group_id="O2" value="-7.131" spread="10.7158"/>
                    <measurement group_id="O3" value="-5.027" spread="12.2383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=162, 166, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.310" spread="10.0187"/>
                    <measurement group_id="O2" value="-6.543" spread="10.2848"/>
                    <measurement group_id="O3" value="-5.421" spread="11.6463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=159, 164, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.503" spread="9.5968"/>
                    <measurement group_id="O2" value="-4.824" spread="11.2452"/>
                    <measurement group_id="O3" value="-4.241" spread="13.3773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=160, 161, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.590" spread="11.5574"/>
                    <measurement group_id="O2" value="-4.691" spread="11.0348"/>
                    <measurement group_id="O3" value="-3.644" spread="11.0906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=160, 163, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.201" spread="11.0082"/>
                    <measurement group_id="O2" value="-3.427" spread="11.2990"/>
                    <measurement group_id="O3" value="-2.939" spread="11.0774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=158, 160, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.418" spread="10.7162"/>
                    <measurement group_id="O2" value="-2.439" spread="11.0752"/>
                    <measurement group_id="O3" value="-1.980" spread="12.9512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=160, 160, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.755" spread="10.7847"/>
                    <measurement group_id="O2" value="-3.085" spread="10.7054"/>
                    <measurement group_id="O3" value="-2.947" spread="12.9953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (n=160, 158, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.073" spread="10.0091"/>
                    <measurement group_id="O2" value="-2.956" spread="9.9486"/>
                    <measurement group_id="O3" value="-2.509" spread="12.1363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=157, 157, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.581" spread="9.8592"/>
                    <measurement group_id="O2" value="-3.435" spread="11.1554"/>
                    <measurement group_id="O3" value="-2.406" spread="11.8012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=155, 154, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.066" spread="10.9462"/>
                    <measurement group_id="O2" value="-2.801" spread="11.0523"/>
                    <measurement group_id="O3" value="-2.808" spread="10.6534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High-Density Lipoprotein - Cholesterol (HDL-C)</title>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>Full analysis set with available data at each time point (indicated by &quot;n&quot;).</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g capsule, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g capsules, orally, twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High-Density Lipoprotein - Cholesterol (HDL-C)</title>
          <population>Full analysis set with available data at each time point (indicated by &quot;n&quot;).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=165, 170, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.849" spread="12.2814"/>
                    <measurement group_id="O2" value="2.184" spread="12.6361"/>
                    <measurement group_id="O3" value="-0.762" spread="11.4762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=164, 168, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.886" spread="13.6679"/>
                    <measurement group_id="O2" value="1.298" spread="12.8820"/>
                    <measurement group_id="O3" value="-0.955" spread="12.9760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=163, 168, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.535" spread="12.5694"/>
                    <measurement group_id="O2" value="1.085" spread="13.1746"/>
                    <measurement group_id="O3" value="-0.561" spread="12.7619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=163, 167, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.276" spread="13.3975"/>
                    <measurement group_id="O2" value="1.699" spread="12.4080"/>
                    <measurement group_id="O3" value="-0.134" spread="12.7453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=162, 166, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.708" spread="14.7306"/>
                    <measurement group_id="O2" value="2.913" spread="13.3232"/>
                    <measurement group_id="O3" value="1.034" spread="14.0619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=159, 164, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.569" spread="14.8251"/>
                    <measurement group_id="O2" value="5.684" spread="14.7141"/>
                    <measurement group_id="O3" value="2.693" spread="14.7185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=160, 161, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.712" spread="16.0076"/>
                    <measurement group_id="O2" value="6.117" spread="15.5220"/>
                    <measurement group_id="O3" value="2.975" spread="15.7048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=160, 163, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.456" spread="16.2378"/>
                    <measurement group_id="O2" value="6.890" spread="14.6459"/>
                    <measurement group_id="O3" value="3.012" spread="14.6151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=158, 160, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.234" spread="15.8749"/>
                    <measurement group_id="O2" value="8.516" spread="14.2641"/>
                    <measurement group_id="O3" value="4.946" spread="15.6107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=160, 160, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.410" spread="18.0364"/>
                    <measurement group_id="O2" value="8.359" spread="15.6201"/>
                    <measurement group_id="O3" value="5.264" spread="15.6110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (n=160, 158, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.983" spread="15.5313"/>
                    <measurement group_id="O2" value="7.182" spread="15.7227"/>
                    <measurement group_id="O3" value="4.533" spread="14.3921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=157, 157, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.191" spread="14.7070"/>
                    <measurement group_id="O2" value="7.144" spread="15.1433"/>
                    <measurement group_id="O3" value="4.499" spread="14.6233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=155, 154, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.738" spread="15.3629"/>
                    <measurement group_id="O2" value="6.932" spread="16.1796"/>
                    <measurement group_id="O3" value="5.183" spread="14.7508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-High-Density Lipoprotein - Cholesterol</title>
        <description>Non-high-density lipoprotein cholesterol was calculated by subtracting high-density lipoprotein cholesterol from total cholesterol.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52</time_frame>
        <population>Full analysis set with available data at each time point (indicated by &quot;n&quot;).</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 2 g</title>
            <description>TAK-085 2 g capsule, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAK-085 4 g</title>
            <description>TAK-085 2 g capsules, orally, twice daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>EPA-E 1.8 g</title>
            <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-High-Density Lipoprotein - Cholesterol</title>
          <description>Non-high-density lipoprotein cholesterol was calculated by subtracting high-density lipoprotein cholesterol from total cholesterol.</description>
          <population>Full analysis set with available data at each time point (indicated by &quot;n&quot;).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=165, 170, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.406" spread="11.2322"/>
                    <measurement group_id="O2" value="-8.831" spread="12.2172"/>
                    <measurement group_id="O3" value="-3.885" spread="12.3062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=164, 168, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.836" spread="11.6718"/>
                    <measurement group_id="O2" value="-9.663" spread="11.6911"/>
                    <measurement group_id="O3" value="-4.185" spread="13.9301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=163, 168, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.355" spread="11.1879"/>
                    <measurement group_id="O2" value="-9.665" spread="11.8662"/>
                    <measurement group_id="O3" value="-6.301" spread="12.7396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=163, 167, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.929" spread="13.2860"/>
                    <measurement group_id="O2" value="-9.674" spread="13.2498"/>
                    <measurement group_id="O3" value="-6.102" spread="15.3247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=162, 166, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.329" spread="12.1200"/>
                    <measurement group_id="O2" value="-9.169" spread="12.6390"/>
                    <measurement group_id="O3" value="-6.941" spread="14.3629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=159, 164, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.911" spread="11.1228"/>
                    <measurement group_id="O2" value="-7.769" spread="13.3944"/>
                    <measurement group_id="O3" value="-5.842" spread="15.4628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=160, 161, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.396" spread="13.6832"/>
                    <measurement group_id="O2" value="-7.643" spread="13.3578"/>
                    <measurement group_id="O3" value="-5.219" spread="13.4854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=160, 163, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.373" spread="13.3296"/>
                    <measurement group_id="O2" value="-6.273" spread="14.3110"/>
                    <measurement group_id="O3" value="-4.186" spread="13.7872"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=158, 160, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.256" spread="13.2490"/>
                    <measurement group_id="O2" value="-5.515" spread="14.4721"/>
                    <measurement group_id="O3" value="-3.574" spread="16.2259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=160, 160, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.285" spread="14.7340"/>
                    <measurement group_id="O2" value="-6.397" spread="14.1767"/>
                    <measurement group_id="O3" value="-4.907" spread="16.5866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (n=160, 158, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.270" spread="12.4442"/>
                    <measurement group_id="O2" value="-5.801" spread="13.3310"/>
                    <measurement group_id="O3" value="-4.134" spread="15.6056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=157, 157, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.796" spread="12.2273"/>
                    <measurement group_id="O2" value="-6.497" spread="14.6818"/>
                    <measurement group_id="O3" value="-4.088" spread="15.0735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n= 155, 154, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.340" spread="13.7408"/>
                    <measurement group_id="O2" value="-5.255" spread="14.9219"/>
                    <measurement group_id="O3" value="-4.830" spread="13.5956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Collection of AEs commenced from the time that the participant was first administered investigational product (Week 0) until the completion of study treatment (52 weeks of administration)</time_frame>
      <desc>At each study visit, the investigator or subinvestigator assessed whether any AEs had occurred. A neutral question, such as “How have you been feeling since your last visit?” asked. Participants reported AEs occurring at any other time during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>TAK-085 2 g</title>
          <description>TAK-085 2 g capsule, orally, once daily for up to 52 weeks.</description>
        </group>
        <group group_id="E2">
          <title>TAK-085 4 g</title>
          <description>TAK-085 2 g capsules, orally, twice daily for up to 52 weeks.</description>
        </group>
        <group group_id="E3">
          <title>EPA-E 1.8 g</title>
          <description>Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Large intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Neurogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="104" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

